Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

Rosmarin, David; Passeron, Thierry; G. Pandya, Amit; E. Grimes, Pearl; E. Harris, John; R. Desai, Seemal; Lebwohl, Mark; Ruer‐Mulard, M.; Sénéschal, Julien; Wolkerstorfer, Albert; Kornacki, Deanna; Sun, Kang; Butler, Kathleen; Ezzedine, Khaled

doi:10.1056/nejmoa2118828

Public

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

Published in New England Journal of Medicine • Oct 19, 2022

Authors:

David Rosmarin

Thierry Passeron

Amit G. Pandya

Abstract

BACKGROUND: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo. METHODS: We conducted two phase 3, double-blind, vehicle-contr...

Subject

Vitiligo

Depigmentation

Ruxolitinib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!